Thomas R. Staab II
2017
In 2017, Thomas R. Staab II earned a total compensation of $1.7M as Senior Vice President and Chief Financial Officer at BioCryst Pharmaceuticals, a 140% increase compared to previous year.
Compensation breakdown
| Bonus | $143,962 |
|---|---|
| Non-Equity Incentive Plan | $130,836 |
| Option Awards | $1,001,288 |
| Salary | $434,002 |
| Other | $13,500 |
| Total | $1,723,588 |
Staab received $1M in option awards, accounting for 58% of the total pay in 2017.
Staab also received $144K in bonus, $130.8K in non-equity incentive plan, $434K in salary and $13.5K in other compensation.
Rankings
In 2017, Thomas R. Staab II's compensation ranked 6,245th out of 14,666 executives tracked by ExecPay. In other words, Staab earned more than 57.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,245 out of 14,666 | 57th |
Division Manufacturing | 2,298 out of 5,772 | 60th |
Major group Chemicals And Allied Products | 729 out of 2,075 | 65th |
Industry group Drugs | 565 out of 1,731 | 67th |
Industry Biological Products, Except Diagnostic Substances | 104 out of 313 | 67th |
Source: SEC filing on May 10, 2018.
Staab's colleagues
We found four more compensation records of executives who worked with Thomas R. Staab II at BioCryst Pharmaceuticals in 2017.
2017
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
2017
William Sheridan
BioCryst Pharmaceuticals
Chief Medical Officer
2017
Yarlagadda Babu
BioCryst Pharmaceuticals
Senior Vice President of Drug Discovery
2017
Lynne Powell
BioCryst Pharmaceuticals